Liminatus Pharma, Inc. Class A Common Stock (LIMN) stock price

Liminatus Pharma, Inc. Class A Common Stock (LIMN) is a Healthcare · Biotechnology company listed on NASDAQ. Price $3.66 (+7.96%), Market cap $0.01B, 52-week low–high $0.17 ~ $26.67.

Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.

Key metrics

Financial statements, price targets, institutional (13F) holdings and related news for Liminatus Pharma, Inc. Class A Common Stock are updated in real time on BlackAll Trade.

Liminatus Pharma, Inc. Class A Common Stock financial summary

Key ratios · profitability · growth

Frequently asked questions

What is the current Liminatus Pharma, Inc. Class A Common Stock (LIMN) stock price?

Liminatus Pharma, Inc. Class A Common Stock trades at $3.66 (+7.96%). Real-time quotes and charts are available on BlackAll Trade.

What is the Liminatus Pharma, Inc. Class A Common Stock (LIMN) market cap?

Liminatus Pharma, Inc. Class A Common Stock has a market cap of about $0.01B.

What does Liminatus Pharma, Inc. Class A Common Stock (LIMN) do?

Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibo